Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

skip to content

Evelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases

Cambridge, MA - March 2, 2020

Read the original article here